HDAC9 and salivary gland cancer: From drug screening data in cancer cell lines collected from GDSC, we saw that TP53 mutated cancer cell lines (breast, ovary, kidney, prostate and salivary gland cancer cell lines) show better sensitivity to the proteasome inhibitor drug Bortezomib, as well as HDAC inhibitor drug Vorinostat (Figures 2a and 2b).